HiberCell
3 known investors
HiberCell develops therapeutic candidates targeting the Integrated Stress Response pathway to address treatment-resistant cancers, relapse, and metastasis. The company focuses on cancer patients who have experienced treatment resistance through novel drug development approaches.
Founders & leadership
JA
Julio Aguirre-Ghiso, Ph.D.Co-Founder
Investors · 3
In the news
- HiberCell Raises $67.4M in Series B; Secures $30M Debt Facilityfinsmes.com · 2021
- HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capitalglobenewswire.com · 2021
- HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics - Mount Sinai Innovation Partnersip.mountsinai.org · 2019
- HiberCell Launches With $60.75 Million Series A to Target Dormant Metastatic Cancer Cells - BioSpacebiospace.com · 2019
- HiberCell Raises $60.75M in Series A Funding - FinSMEsfinsmes.com · 2019
- HiberCell 5/20/2021 Capital Raise - Gaebler.com Venture Capital Databasegaebler.com